Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)

Leonard Lothstein, D. Parker Suttle, J. Brent Roaten, Yoshihiro Koseki, Mervyn Israel, Trevor W. Sweatman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of topoisomerase II, capable of preventing topoisomerase II activity on DNA. The concentration of AD 288 required to inhibit the topoisomerase II-catalyzed decatenation of linked networks of kinetoplast DNA was comparable to that for DOX. However, AD 288 did not stabilize cleavable complex formation or stimulate topoisomerase II-mediated DNA cleavage. In addition, AD 288 inhibited the formation of cleavable complexes by etoposide in a concentration-dependent manner. Human CCRF-CEM cells and murine J774.2 cells exhibiting resistance against DOX, teniposide, or 3'-hydroxy-3'-deaminodoxorubicin through reduced topoisomerase II activity remained sensitive to AD 288. These studies suggest that AD 288 inhibits topoisomerase II activity by preventing the initial non-covalent binding of topoisomerase II to DNA. Since AD 288 is a potent DNA intercalator, catalytic inhibition is achieved by prohibiting access of the enzyme to DNA binding sites. These results also demonstrate that specific substitutions on the aminosugar of DOX can alter the mechanism of topoisomerase II inhibition. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)1621-1628
Number of pages8
JournalBiochemical Pharmacology
Volume60
Issue number11
DOIs
StatePublished - Dec 1 2000

Fingerprint

Catalytic DNA
Type II DNA Topoisomerase
Doxorubicin
DNA
Kinetoplast DNA
Teniposide
Intercalating Agents
Topoisomerase II Inhibitors
N-benzyladriamycin
DNA Cleavage
Etoposide
Substitution reactions
Binding Sites

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Lothstein, L., Suttle, D. P., Roaten, J. B., Koseki, Y., Israel, M., & Sweatman, T. W. (2000). Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochemical Pharmacology, 60(11), 1621-1628. https://doi.org/10.1016/S0006-2952(00)00472-X

Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). / Lothstein, Leonard; Suttle, D. Parker; Roaten, J. Brent; Koseki, Yoshihiro; Israel, Mervyn; Sweatman, Trevor W.

In: Biochemical Pharmacology, Vol. 60, No. 11, 01.12.2000, p. 1621-1628.

Research output: Contribution to journalArticle

Lothstein, L, Suttle, DP, Roaten, JB, Koseki, Y, Israel, M & Sweatman, TW 2000, 'Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)', Biochemical Pharmacology, vol. 60, no. 11, pp. 1621-1628. https://doi.org/10.1016/S0006-2952(00)00472-X
Lothstein, Leonard ; Suttle, D. Parker ; Roaten, J. Brent ; Koseki, Yoshihiro ; Israel, Mervyn ; Sweatman, Trevor W. / Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). In: Biochemical Pharmacology. 2000 ; Vol. 60, No. 11. pp. 1621-1628.
@article{fe575f1e82204039bd86bba8261fcd06,
title = "Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)",
abstract = "N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of topoisomerase II, capable of preventing topoisomerase II activity on DNA. The concentration of AD 288 required to inhibit the topoisomerase II-catalyzed decatenation of linked networks of kinetoplast DNA was comparable to that for DOX. However, AD 288 did not stabilize cleavable complex formation or stimulate topoisomerase II-mediated DNA cleavage. In addition, AD 288 inhibited the formation of cleavable complexes by etoposide in a concentration-dependent manner. Human CCRF-CEM cells and murine J774.2 cells exhibiting resistance against DOX, teniposide, or 3'-hydroxy-3'-deaminodoxorubicin through reduced topoisomerase II activity remained sensitive to AD 288. These studies suggest that AD 288 inhibits topoisomerase II activity by preventing the initial non-covalent binding of topoisomerase II to DNA. Since AD 288 is a potent DNA intercalator, catalytic inhibition is achieved by prohibiting access of the enzyme to DNA binding sites. These results also demonstrate that specific substitutions on the aminosugar of DOX can alter the mechanism of topoisomerase II inhibition. (C) 2000 Elsevier Science Inc.",
author = "Leonard Lothstein and Suttle, {D. Parker} and Roaten, {J. Brent} and Yoshihiro Koseki and Mervyn Israel and Sweatman, {Trevor W.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1016/S0006-2952(00)00472-X",
language = "English (US)",
volume = "60",
pages = "1621--1628",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)

AU - Lothstein, Leonard

AU - Suttle, D. Parker

AU - Roaten, J. Brent

AU - Koseki, Yoshihiro

AU - Israel, Mervyn

AU - Sweatman, Trevor W.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of topoisomerase II, capable of preventing topoisomerase II activity on DNA. The concentration of AD 288 required to inhibit the topoisomerase II-catalyzed decatenation of linked networks of kinetoplast DNA was comparable to that for DOX. However, AD 288 did not stabilize cleavable complex formation or stimulate topoisomerase II-mediated DNA cleavage. In addition, AD 288 inhibited the formation of cleavable complexes by etoposide in a concentration-dependent manner. Human CCRF-CEM cells and murine J774.2 cells exhibiting resistance against DOX, teniposide, or 3'-hydroxy-3'-deaminodoxorubicin through reduced topoisomerase II activity remained sensitive to AD 288. These studies suggest that AD 288 inhibits topoisomerase II activity by preventing the initial non-covalent binding of topoisomerase II to DNA. Since AD 288 is a potent DNA intercalator, catalytic inhibition is achieved by prohibiting access of the enzyme to DNA binding sites. These results also demonstrate that specific substitutions on the aminosugar of DOX can alter the mechanism of topoisomerase II inhibition. (C) 2000 Elsevier Science Inc.

AB - N-Benzyladriamycin (AD 288) is a highly lipophilic, semi-synthetic congener of doxorubicin (DOX). Unlike DOX, which stimulates double-stranded DNA scission by stabilizing topoisomerase II/DNA cleavable complexes, AD 288 is a catalytic inhibitor of topoisomerase II, capable of preventing topoisomerase II activity on DNA. The concentration of AD 288 required to inhibit the topoisomerase II-catalyzed decatenation of linked networks of kinetoplast DNA was comparable to that for DOX. However, AD 288 did not stabilize cleavable complex formation or stimulate topoisomerase II-mediated DNA cleavage. In addition, AD 288 inhibited the formation of cleavable complexes by etoposide in a concentration-dependent manner. Human CCRF-CEM cells and murine J774.2 cells exhibiting resistance against DOX, teniposide, or 3'-hydroxy-3'-deaminodoxorubicin through reduced topoisomerase II activity remained sensitive to AD 288. These studies suggest that AD 288 inhibits topoisomerase II activity by preventing the initial non-covalent binding of topoisomerase II to DNA. Since AD 288 is a potent DNA intercalator, catalytic inhibition is achieved by prohibiting access of the enzyme to DNA binding sites. These results also demonstrate that specific substitutions on the aminosugar of DOX can alter the mechanism of topoisomerase II inhibition. (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0034575672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034575672&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(00)00472-X

DO - 10.1016/S0006-2952(00)00472-X

M3 - Article

VL - 60

SP - 1621

EP - 1628

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -